This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
by Kinjel Shah
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
by Zacks Equity Research
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
by Kinjel Shah
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
by Kinjel Shah
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
by Kinjel Shah
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
by Kinjel Shah
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
by Zacks Equity Research
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
by Zacks Equity Research
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?
by Kinjel Shah
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 44.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
by Zacks Equity Research
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
by Kinjel Shah
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Top Analyst Reports for AbbVie, Lockheed Martin & Dell
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin Corporation (LMT) and Dell Technologies Inc. (DELL), as well as a micro-cap stock Hamilton Beach Brands Holding Company (HBB).
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer
by Zacks Equity Research
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.